Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Parent MD Anderson phase 2 trial of definitive radiation without systemic therapy for oligometastatic RCC (org study ID 2018-0203). ClinicalTrials.gov API v2 on 13 Nov 2026: SUSPENDED, whyStopped 'PI Request', status verified Oct 2026, actual enrollment 123, start 2018-06-14, primary completion 2024-08-20. The 2025 Lancet Oncol paper (PMID 40915303) reports 121 ITT / 120 per-protocol and states the trial is closed to new enrolment.

M.D. Anderson Cancer Center